Search results for "RICS"

showing 10 items of 14086 documents

The Right Job and the Job Right: Novelty, Impact and Journal Stratification in Science

2018

Though Science is traditionally associated with creative behavior, concerns have been raised on its professional procedures being sufficiently open to innovative research. Thanks to a new measurement of novelty based on the frequencies of pairwise combinations of article keywords calculated on the set of all research articles published from 1999 to 2013 in the journals referenced by the WoS (more than ten million papers), we find no evidence of shrinking novelty in science over that period. Novel contributions are more often performed in larger teams that span more institutional boundaries and geographic areas. High novelty increases citations by more than forty percent and the odds of a “b…

Actuarial sciencemedia_common.quotation_subjectScientometricsCreative behaviorNoveltyPairwise comparisonQuality (business)ResizingPsychologySet (psychology)Period (music)media_commonOddsSSRN Electronic Journal
researchProduct

Acute effects of short-duration isolated static stretching or combined with dynamic exercises on strength, jump and sprint performance

2013

Summary Objective This study aimed to investigate the acute effects of a short-duration isolated static stretching or combined with dynamic plyometric exercises on the performance of some anaerobic parameters (strength, jumping and sprinting). Methods During three distinct sessions and after a standardized warm-up, 15 participants randomly performed static stretching exercises alone, static stretching combined with plyometric exercises and no stretch. Total stretch duration was 20 seconds long per muscle group (quadriceps, hamstrings and calf muscles). Tests included maximal quadriceps muscle strength, countermovement jumps and 15 m sprints. Results Whatever the condition, maximal strength …

Acute effectsmedicine.medical_specialtymedicine.disease_causeStatic stretchingVertical jumpJumpingPhysical medicine and rehabilitationSprintJumpmedicinePhysical therapyPlyometricsOrthopedics and Sports MedicineAnaerobic exerciseMathematicsScience & Sports
researchProduct

Acute leukemia following anticancer treatment

1975

Acute leukemiaAnticancer treatmentbusiness.industryPediatrics Perinatology and Child HealthCancer researchMedicinebusinessThe Journal of Pediatrics
researchProduct

Survival of Myeloid Malignancies in EUROPE: Results of the HAEMACARE Project.

2009

Abstract Abstract 3911 Poster Board III-847 Background Updated ICD-O and WHO classifications of Haematological Malignancies (HMs) take into account cell lineage, genotype, morphological aspects, immuno-histochemical and genetic characteristics, and clinical behaviour of the disease, dividing Lymphoid and Myeloid neoplasms in subcategories with possible similar aetiology or prognosis. Thus, good quality of morphological data on HMs is capital. The HAEMACARE project aimed to increase standardization and the availability of Cancer Registries (CRs) morphological data on HMs, in order to improve comparability of incidence, survival and prevalence across Europe. This study aims to present the HAE…

Acute leukemiaPediatricsmedicine.medical_specialtyMyeloidRelative survivalbusiness.industryIncidence (epidemiology)ImmunologyMyeloid leukemiaCell BiologyHematologyDiseasemedicine.diseaseBiochemistryLeukemiamedicine.anatomical_structureEtiologymedicinebusinessDemographyBlood
researchProduct

Acute Promyelocytic Leukemia during Pregnancy: A Systematic Review of the Literature

2020

The management of pregnant women with acute promyelocytic leukemia (APL) is a challenging situation where limited evidence-based information is available. We performed a systematic literature review to analyze the outcomes reported for both mother and fetus when APL is diagnosed during pregnancy. PubMed, Scopus and Web of Science databases were systematically searched to identify studies reporting cases of APL during pregnancy. Sixty-six articles met the eligibility criteria (53 single case reports). Ninety-two patients were eligible for induction therapy, with most them being treated with all-trans retinoic acid alone (32%) or combined with chemotherapy (43%), while the remaining patients …

Acute promyelocytic leukemiaCancer Researchmedicine.medical_specialtyAbortionchemotherapylcsh:RC254-282Article03 medical and health sciences0302 clinical medicineObstetrics and gynaecologymedicineNeonatologyPregnancyFetal viabilityRespiratory distressObstetricsbusiness.industryGestational ageacute promyelocytic leukemialcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseall-trans retinoic acidarsenic trioxideOncology030220 oncology & carcinogenesispregnancybusiness030215 immunologyCancers
researchProduct

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup …

2016

Abstract Background: Standard therapy of acute promyelocytic leukemia has long relied on the combination of All-trans-retinoic acid (ATRA) and chemotherapy. The introduction of arsenic trioxide (ATO) in APL treatment has allowed achievement of similarly high remission and survival rates coupled with significantly reduced myelosuppression. Recent results of the APL0406 trial by the GIMEMA-AMLSG-SAL study groups showed that the combination of ATRA and arsenic trioxide (ATO) is superior to standard ATRA and chemotherapy (CHT) in front-line therapy of low/intermediate risk acute promyelocytic leukemia (APL). The implications of these results for the clinical practice of APL patients in Germany …

Acute promyelocytic leukemiaChemotherapyPediatricsmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologyComplete remissionCell BiologyHematologymedicine.diseaseBiochemistryChemotherapy regimenRegimenchemistry.chemical_compoundchemistryMedicineCumulative incidenceObservational studyArsenic trioxidebusinessneoplasmsBlood
researchProduct

First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic…

2017

Recently, studies in adults with acute promyelocytic leukemia (APL) showed high cure rates in low-risk patients treated with all-trans retinoid acid (ATRA) and arsenic trioxide (ATO), while toxicities were significantly reduced compared to the standard treatment with ATRA and chemotherapy. Here we report about first experience with 11 pediatric patients with low-risk APL treated with ATRA and ATO. All patients stayed in molecular remission. All suffered from hyperleukocytosis. Two patients experienced reversible severe side effects. One suffered from osteonecroses at both femurs, seizures, as well as posterior reversible encephalopathy syndrome, the other patient had an abducens paresis.

Acute promyelocytic leukemiaMalemedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentMedizinTretinoinGastroenterologyArsenicals03 medical and health scienceschemistry.chemical_compound0302 clinical medicineArsenic TrioxideLeukemia Promyelocytic AcuteTretinoinInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansRetinoidArsenic trioxideChildneoplasmsParesisRetrospective StudiesChemotherapybusiness.industryStandard treatmentInfantPosterior reversible encephalopathy syndromeOxidesHematologymedicine.diseaseSurgeryTreatment OutcomeOncologychemistry030220 oncology & carcinogenesisChild PreschoolPediatrics Perinatology and Child HealthFemalemedicine.symptombusiness030215 immunologymedicine.drug
researchProduct

Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia - Updated Results of the Ital…

2014

Abstract Background: We recently showed that the combination of ATRA and arsenic trioxide (ATO) is at least not inferior and possibly superior to standard ATRA and chemotherapy (CHT) in the front-line management of low/intermediate risk APL (Italian-German APL 0406 trial; Lo-Coco et al., NEJM 2013). We report herein on the extended and final series of 276 patients (162 were in the previous report) with the last case being enrolled into the study in January 2013. Methods: The APL0406 study was a prospective, open-label, randomized intergroup trial conducted by the Italian GIMEMA and the German SAL and AMLSG study groups. Eligible patients were adults aged 18-<71 years with newly diagnosed…

Acute promyelocytic leukemiaPediatricsmedicine.medical_specialtyChemotherapyAnthracyclinebusiness.industrymedicine.medical_treatmentImmunologyCell BiologyHematologyOff-label usemedicine.diseaseBiochemistrychemistry.chemical_compoundchemistryInternal medicineCohortmedicineIdarubicinCumulative incidenceArsenic trioxidebusinessmedicine.drug
researchProduct

Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study

2015

Abstract Background: Acute promyelocytic leukemia (APL) is a rare subtype of childhood acute myeloid leukemia (AML). Bleeding complications occur in 80% of patients at diagnosis and contribute to a higher incidence of early death (ED) in APL compared to other AML subtypes. However, estimates of ED in pediatric APL are imprecise and factors associated with ED in children with APL are unknown. Objectives: To determine the incidence and predictors of ED, defined as death within 60 days from presentation, in childhood APL. Methods: We conducted a retrospective international analysis of children diagnosed with APL between January 1993 and December 2013. The study included 236 patients from the I…

Acute promyelocytic leukemiaPediatricsmedicine.medical_specialtybusiness.industryIncidence (epidemiology)ImmunologyChildhood Acute Myeloid LeukemiaRetrospective cohort studyCell BiologyHematologyOdds ratiomedicine.diseaseBiochemistryClinical trialmedicinebusinessBody mass indexLung allocation scoreBlood
researchProduct

Treatment Results In Acute Myeloid Leukemia Over a Time Period Of 20 Years: Analysis Of The German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)

2013

Abstract Background Overall survival (OS) in acute myeloid leukemia (AML) treated with intensive chemotherapy has improved over the last 20 year especially in younger adults (18-60 years) but still remains poor in older patients (>60 years) (Döhner et al. Blood 2010). The German-Austrian AMLSG performed controlled prospective treatment trials since 1993 starting with a risk-adapted approach (phase I, 1993-1997), followed by randomized and risk-adapted treatment strategies based on cytogenetic risk groups (phase II, 1997-2002); since 2003 addition of differentiating agents and HiDAC inhibitors to intensive induction therapy was evaluated (phase III, 2003-2007). Of note, until 2007 younger…

Acute promyelocytic leukemiamedicine.medical_specialtyPediatricsmedicine.medical_treatmentImmunologyHematopoietic stem cell transplantationBiochemistry03 medical and health sciences0302 clinical medicineInternal medicinemedicineMyelofibrosisNeoadjuvant therapy030304 developmental biology0303 health sciencesChemotherapybusiness.industryMortality rateCell BiologyHematologymedicine.diseasePomalidomideChemotherapy regimen3. Good healthbusiness030215 immunologymedicine.drugBlood
researchProduct